TL;DR
This study investigates the use and discontinuation of long-acting injectable (LAI) antipsychotics in children and adolescents diagnosed with schizophrenia, using Medicaid claims data. It reveals that while LAI use is increasing, there are racial disparities in discontinuation rates, with White individuals showing a lower risk of discontinuing paliperidone palmitate compared to Black individuals.
What Problem Does This Paper Address?
Schizophrenia in children and adolescents is a serious, though rare, condition that can be particularly debilitating, often presenting with more severe negative symptoms and cognitive impairments than adult-onset schizophrenia. Antipsychotics are the primary treatment, with second-generation antipsychotics (SGAs) generally preferred over first-generation ones (FGAs) due to a better side-effect profile. While oral SGAs are common, long-acting injectable (LAI) antipsychotics offer potential benefits like improved adherence by reducing the need for daily dosing. However, research on LAI use and discontinuation in pediatric populations is scarce, especially concerning racial and ethnic differences. This paper aims to fill this gap by analyzing real-world data on LAI prescribing and discontinuation patterns in a large cohort of children and adolescents covered by Medicaid.
Methods
The researchers utilized the Merative MarketScan Multi-State Medicaid Database, a large claims database covering millions of individuals. They identified children and adolescents (ages 2-17) with a diagnosis of schizophrenia or related disorders who received at least one LAI antipsychotic prescription between January 1, 2017, and December 31, 2021.
Key methodological aspects include:
- Cohort Identification: Patients were identified using ICD-10-CM codes for schizophrenia and LAI antipsychotic National Drug Codes (NDCs).
- Index Date: Defined as the date of the first LAI antipsychotic prescription.
- Discontinuation Definition: A continuous medication gap of 60 days or more after the last day of LAI coverage was used to define discontinuation. This approach is considered conservative.
- Statistical Analysis:
- Descriptive statistics were used to summarize prescribing and discontinuation rates.
- Kaplan-Meier survival curves were employed to visualize discontinuation over time.
- Cox proportional hazards (CoxPH) models were used to compare discontinuation hazards between different LAI agents and to assess the impact of race/ethnicity, adjusting for age, gender, and health plan type.
Datasets
The study used the Merative MarketScan Multi-State Medicaid Database. This dataset contains prescription drug claims, inpatient, and outpatient service records for millions of individuals covered by Medicaid programs across various US states. The database provides comprehensive healthcare utilization data, including demographic information, diagnosis codes, and prescription details. The study focused on the subset of this database representing children and adolescents (ages 2-17).
Key Insights and Ideas
- LAI Use in Pediatrics is Growing: The study confirms that LAI antipsychotics are being prescribed to children and adolescents, aligning with the trend of using SGAs in this population.
- Paliperidone and Aripiprazole Dominate: Paliperidone palmitate (1-month formulation) and aripiprazole formulations were the most frequently prescribed LAI antipsychotics in this pediatric cohort.
- Racial Disparity in Discontinuation: A significant finding is the racial difference in discontinuation rates for LAI paliperidone palmitate 1 month. White individuals had a substantially lower risk of discontinuing this medication compared to Black individuals.
- Hypotheses for Disparities: The authors propose potential explanations for these disparities, including differences in susceptibility to extra-pyramidal symptoms (EPS) and metabolic/endocrine side effects, with Black individuals potentially being more prone to these issues with paliperidone.
- Need for Further Research: The study highlights the critical need for more research to understand the underlying reasons for these discontinuation differences, particularly in the pediatric population.
Key Results
- A total of 1,277 patients (out of 67,502 initially identified) met the inclusion criteria.
- The average age of the participants was 15.4 ± 1.7 years, with ages ranging from 7 to 17.
- Approximately 59% of the cohort were male.
- The most common racial identifications were Black (48%) and White (38%).
- 94% of the population received LAI SGAs.
- The most common LAI antipsychotics prescribed were paliperidone palmitate 1 month (40%) and aripiprazole formulations (48%).
- When controlling for age, gender, and plan type, discontinuation rates for paliperidone palmitate 1 month and aripiprazole formulations did not differ between racial groups.
- However, LAI paliperidone palmitate 1 month was associated with a 46% lower hazard of discontinuation for White compared to Black populations (HR=0.54; p=0.01).
- A sub-analysis focusing on the adolescent population also showed no differences in discontinuation rates between Black and White populations for these agents.
- Further analysis indicated that among White individuals, discontinuation rates did not differ between paliperidone palmitate 1 month and aripiprazole formulations. However, among Black individuals, aripiprazole formulations showed a statistically significant lower discontinuation rate compared to paliperidone palmitate 1 month (HR=0.57; p=0.004).
Limitations and Future Work
The authors acknowledge several limitations:
- Inability to Determine Reasons for Discontinuation: The study could not ascertain the specific reasons (e.g., side effects, efficacy, patient preference) behind discontinuation.
- Reporting and Coding Biases: Potential for reporting and coding errors in claims data.
- Limited Scope of LAI Agents: Only paliperidone palmitate 1-month formulation was evaluated for racial differences; longer-acting formulations (e.g., 3- or 6-month) were not included.
- Lack of State-Level Identifiers: The database does not provide state-level identifiers, limiting the ability to evaluate geographic representation and regional variations, which could influence prescribing patterns and access to care.
- Generalizability: While the Medicaid database offers broad coverage, the absence of state-specific data might introduce regional bias and affect generalizability.
Future work should focus on:
- Investigating the specific reasons for discontinuation in child and adolescent populations.
- Conducting prospective comparative studies to directly assess LAI paliperidone palmitate against aripiprazole formulations in this age group.
- Exploring the economic impact of LAI antipsychotics in this population.
- Utilizing state Medicaid databases to refine generalizability and identify state-specific effects.
- Evaluating longer-acting LAI formulations.
Summary updated